Long Shenrong announced that its holding subsidiary, Puan Pharmaceutical, has obtained the qualification for the listing and sale of Tongmai Oral Liquid.

On September 19th, Longshenrong announced that its holding subsidiary, Gansu Puan Pharmaceutical Co., Ltd., recently obtained the "On-site Inspection and First Batch Product Inspection Registration Document before Drug Marketing" approved and issued by the Gansu Provincial Drug Administration, and Tongmai Oral Liquid officially has the qualifications for marketing and sales. This product functions to promote blood circulation and opens up the meridians, and is used for ischemic cardiovascular and cerebrovascular diseases, arteriosclerosis, cerebral thrombosis, cerebral ischemia, angina pectoris, and coronary heart disease. Due to various factors affecting the production and sales of drugs, there is uncertainty. Investors are advised to make decisions cautiously and pay attention to investment risks.